Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.

导出 LinkOut

翻译打印收藏纠错

作者： Faraat,Ali ^[1] ; Anam,Ilyas ^[2]

作者单位： Department of Inspection and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority, Plot 112, International Finance Park, Gaborone, Botswana. Electronic address: frhtl6@gmail.com. ^[1] SPER, Jamia Hamdard, New Delhi, India. ^[2]

关键词 BLM Belumosudil Chronic Graft-Versus-Host Disease KD025 Kinase Inhibitor REZUROCK(TM)ROCK Rock-2 Inhibitor SLx-2119 cGVHD

主题词乙酰胺类(Acetamides);成年人(Adult);儿童(Child);移植物抗宿主病(Graft vs Host Disease);人类(Humans);硬皮病, 系统性(Scleroderma, Systemic);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)

DOI 10.1016/j.retram.2022.103343

PMID 35339032

发布时间 2022-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Current research in translational medicine

2022年70卷3期

103343页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.

Current research in translational medicine

相似文献

Current research in translational medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.

Current research in translational medicine

相似文献

Current research in translational medicine

相关期刊

检索历史清除